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Clinical Observations 
Effects of the Ganning Formula (㙱ᅕᮍon Liver Fibrosis in Patients 
With Chronic Hepatitis B 
DENG Xin 䙧䨿, LIANG Jian ṕع, WU Fa-sheng ਈথ㚰, LI Yan-bo ᴢ㡇⊶, and TANG Yan-fang ૤㡇㢇
Objective: To investigate the clinical efficacy and safety of the Ganning formula (㙱ᅕᮍ) for the treatment of liver 
fibrosis in patients with chronic hepatitis B. 
Methods: In a multicenter, randomized, controlled clinical trial, 150 patients with liver fibrosis secondary to
hepatitis B virus (HBV) infection were randomly assigned in equal numbers to receive either the Ganning formula 
(a Chinese herbal decoction; active treatment group) or oral entecavir (control group) for two 3-month courses. 
Patients were monitored for any treatment-induced changes in liver function test parameters (ALT, AST, and GGT), 
liver fibrosis markers (LN, HA, IV-C, and PCIII), HBV DNA level, hepatosplenic imaging, quality of life scores, or 
psychological and social functioning scores. Patients were also observed for any adverse effects. 
Results: After treatment, patients in both groups experienced significant improvements in liver function, HBV 
DNA load, hepatosplenic B-mode ultrasonography, quality of life, and psychological and social functioning (P<0.05 
or P<0.01). Patients receiving the Ganning formula achieved greater improvements in HA, IV-C, quality of life, and 
psychological and social functioning compared with those on entecavir (P<0.05 or P<0.01). There were no 
abnormal changes in blood tests, urine, feces, renal function, or electrocardiogram. Additionally, no adverse effects 
were observed in any patients in either group. 
Conclusions: The Ganning formula appears to have the potential to inhibit liver fibrosis and therefore improve liver 
function by inhibiting HBV replication in patients with chronic hepatitis B. Additionally, this formula is helpful in 
improving quality of life and psychological and social functioning. 
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Liver fibrosis is a common pathological basis of all 
chronic liver diseases and an inevitable stage in the 
progression to liver cirrhosis.1,2 Chronic hepatitis B has 
been identified as the main cause of liver fibrosis in the 
Chinese population.3 Currently, this stage is considered 
to be reversible but no optimal therapeutic regimens have 
been available in clinical practice because of the 
complexity of mechanisms involved in the development 
of liver fibrosis and the long-term nature of this 
condition.4,5 In our practice, we observed favorable 
efficacy of the Ganning formula (㙱ᅕᮍ ) in the 
treatment of hepatic fibrosis in patients with chronic 
hepatitis. We report our experience with the use of this 
formula. 
METHODS 
General Data 
One hundred fifty outpatients or inpatients with liver 
fibrosis caused by chronic hepatitis B were enrolled in 
Ruikang Hospital of Guangxi Traditional Chinese 
Medical University, the First Hospital of Guangxi 
Traditional Chinese Medical University, Liuzhou 
Hospital of Traditional Chinese Medicine, and the First 
Hospital of Jiangxi University of Traditional Chinese 
Medicine between January 2007 and December 2010. In
a multicenter stratified randomization design, the patients 
were randomized equally to receive the Ganning formula 
(active treatment group) or oral entecavir (control group). 
Patients assigned to the active treatment group included 
53 men and 22 women with a mean age of 39.32±11.24 
years (range, 21–59 years) and a mean disease duration 
of 11.52±6.13 years (4.5–25 years). In the control group, 
there were 50 men and 25 women who had a mean age 
of 37.54±9.46 years (23–58 years) and a mean disease 
duration of 10.91±5.34 years (6–28 years). Patients in 
both groups were comparable because  no significant 
between-group differences in the constituent ratio of sex, 
age and disease duration were identified by the Ȥ2 test 
(P>0.05). This clinical trial was approved by the Ethics 
Committee of Guangxi Traditional Chinese Medical 
University and conducted in accordance with the Chinese 
Good Clinical Practice/the Helsinki Declaration. All the 
participants provided informed consent. 
Diagnostic Criteria 
Chronic hepatitis B was diagnosed according to the 
Guidelines for Prevention and Treatment of Chronic 
Hepatitis B revised by the Chinese Society of 
Hepatology, Chinese Medical Association (CMA) and 
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the Chinese Society of Infectious Diseases, CMA in 
December 2005.6 The diagnosis of liver fibrosis 
(nontraumatic) was based on the Consensus on 
Diagnosis and Outcome Assessment of Liver Fibrosis
developed by the Liver Fibrosis Group of the Chinese 
Society of Hepatology, CMA in 2002.7
Inclusion Criteria 
Patients of either sex were eligible for entry into this 
study if they 1) had chronic hepatitis B and liver fibrosis 
that met the respective diagnostic criteria described 
above, 2) were aged 18–60 years, 3) had not used 
antiviral agents or immunomodulators within 6 months 
prior to entry, 4) agreed not to use other observational 
drugs, systemic antiviral agents, cytotoxic agents, 
corticosteroids, immunomodulators, drugs that may 
reduce liver enzymes and alleviate jaundice, or other 
Chinese herbal preparations, and 5) were willing to 
participate in the study, complete prespecified treatment 
courses and signed the informed consent document. 
Exclusion Criteria 
Patients were excluded if they 1) were younger than 18 
years or older than 60 years, 2) had concomitant or 
superimposed hepatic infections caused by other viruses, 
3) had hepatitis caused by laboratory-confirmed drug 
poisoning or alcoholism, 4) had autoimmune hepatitis 
with hepatitis B, 5) had comorbidities such as liver 
cancer, hepatic encephalopathy, and decompensated liver 
cirrhosis, 6) had severe jaundice (total bilirubin 10 
times the upper limit of normal [ULN]), ascites or severe 
comorbidities of the cardiovascular system, pulmonary, 
renal, endocrine, or hematopoietic systems, 7) had 
psychiatric disorders, 8) were pregnant or breastfeeding, 
9) had a history of hypersensitivity to Chinese herbal 
compounds or nucleoside antiviral agents, 10) were not 
able to complete the study (including patients with 
incomplete data and those who prematurely discontinued 
the study), and 11) did not meet the diagnostic and 
inclusion criteria. 
Elimination Criteria 
Elimination criteria included: 1) patients who were 
co-administered with other Chinese or Western 
medications for the diseases described above during the 
observation period; and 2) patients who had to 
discontinue treatment because of occurrences of 
unexpected events during the observation period. 
Treatment Regimens 
According to recommendations from the guidelines for 
prevention and treatment of chronic hepatitis B by the 
Chinese Society of Hepatology and the Chinese Society 
of Infectious Diseases, CMA, patients assigned to the 
control group were orally given entecavir 0.5 mg once 
daily for two 3-month courses. Patients in the active 
treatment group received the Ganning formula in the
form of a packed decoction (200 mL/pack) prepared by 
the Chinese Drug Preparation Room at Ruikang 
Hospital. The Ganning formula ingredients include 
Huang Qi (Astragalus membranaceus) 15 g, Bai Zhu 
(Atractylodes macrocephala Koidz) 25 g, Bai Shao 
(Radix Paeoniae Alba) 15 g, Dang Gui (Radix Angelica) 
10 g, Bie Jia (Carapax Trionycis) 15 g, Ze Lan (Herba 
Lycopi) 10 g, Hu Lu Cha (Tadehagi Ohashi) 10 g and 
Meng Lao Hu (Catharanthus roseus) 10 g. Patients took 
200 mL of warmed decoction once in the morning and 
once in the evening for two 3-month courses. 
Outcome Measures 
1) Serum Markers of Liver Fibrosis: Hyaluronic acid 
(HA), laminin (LN), type IV collagen (IV-C) and 
procollagen III (PC-III) levels in serum were measured 
by radioimmunoassay before and after treatment. 2) 
Liver Function Parameters: Alanine aminotransferase
(ALT), aspartate aminotransferase (AST) and 
Ȗ-glutamyltransferase (GGT) levels were measured by a 
fully automatic biochemistry analyzer before and after 
treatment. 3) Hepatitis B virus (HBV)-DNA: HBV-DNA 
was analyzed by fluorescent quantitative polymerase 
chain reaction before and after treatment. 4) 
Hepatosplenic B-mode Ultrasonography: Ultrasonic 
assessment of hepatosplenic quantitative parameters 
(inner diameter of the portal vein and splenic thickness) 
was performed on an up-to-date Hewlett Packard Sonos 
1000 ultrasound system (Hewlett Packard, USA) before 
and after treatment. 5) Quality of Life Scores: Quality of 
life was scored using a short version of the World Health 
Organization Quality of Life assessment instrument 
(WHOQOL-BREF) before and after treatment.8,9 6) 
Psychological and Social Functioning Scores: 
Psychological state was assessed by the Zung 
Self-Rating Anxiety Scale (SAS) and Self-Rating 
Depression Scale (SDS). Patients were considered to 
have anxiety or depression if the SAS or SDS scores 
were 50 or higher.10 Patients with a total score of less 
than 50 were considered to be normal. The severity of 
the disorder was classified as mild (score, 50–60), 
moderate (61–70) and severe (>70). Social functioning 
was evaluated using the Social Disability Screening 
Schedule (SDSS) in the Manual of Rating Scales for 
Psychiatry compiled by Zhang.11 A total SDSS sore of 2 
is suggestive of the presence of social disability. 7) 
Safety Parameters: Evaluation of blood, urine, feces, 
renal function (BUN, Cr) and electrocardiogram were
performed before and after treatment. 8) Adverse Effects: 
The number of patients experiencing adverse effects 
during treatment was calculated. 
Outcome Classification 
According to the guidelines for the diagnosis and 
treatment of liver fibrosis in integrative medicine 
practice developed by the Liver Disease Committee, 
Chinese Association of Integrative Medicine in August 
2006,12 treatment outcomes were classified as follows: 1) 
Significant response: liver histopathology shows a 
decrease in liver fibrosis stage by at least two stages; any 
two of the liver fibrosis serum markers (PC-III, HA, LN 
and IV-C content) are decreased by at least 50% or 
return to normal after treatment; serum liver function 
parameters return to near-normal and symptoms are 
significantly improved. 2) Response: after treatment, any 
two of the liver fibrosis serum markers (PC-III, HA, LN 
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and IV-C content) are decreased by at least 25%; serum 
liver function parameters are improved and/or liver 
fibrosis stage is decreased by one stage on liver 
histopathology; and symptoms are improved. 3) Failure: 
failure to meet the response criteria described above. 
Statistical Analysis 
Database establishment, data entry, and statistical 
analysis were conducted using the SPSS 17.0 (SPSS Inc.) 
statistical software package. Measurement data that were 
normally distributed are reported as x ±S.
Between-group comparisons were performed by the t test. 
If there was heterogeneity of variance, then the t test was 
used. Measurement data with a skewed distribution are 
expressed as M (QR). Comparisons between two groups 
were performed using the rank sum test. Enumeration 
data were analyzed by the (corrected) chi-square test or 
the Fisher’s exact probability test. Comparisons of 
ranked data were performed using the rank sum test. 
HBV-DNA viral load was converted to log values and 
negative values were not included in calculations. 
RESULTS 
Overall Response Rates  
Overall, the proportion of patients responding to the 
assigned treatment (the Ganning formula, 78.67% vs. 
entecavir, 84%) was not significantly different between 
both groups (P>0.05, Table 1). 
Changes in Liver Function 
After treatment, patients in both groups experienced 
significant decreases in ALT, AST and GGT levels 
(P<0.01). The decrease in GGT levels was significantly 
greater in the active treatment group than that in the 
control group (P<0.01, Table 2). 
Changes in HBV-DNA 
After treatment, a significant decrease in viral load was 
observed in both groups (P<0.01, Table 3). Data in the 
table are the natural logarithms of the number of virus 
copies. 
Changes in Liver Fibrosis Markers 
Before treatment, HA, IV-C and PC-III levels were all 
above the normal reference range in patients in both 
groups. After treatment, patients receiving the Ganning 
formula experienced a significant decrease in HA, IV-C 
and PC-III levels (P<0.01) and those treated with oral 
entecavir had a significant reduction in HA and IV-C 
levels compared with those before treatment (P<0.01). 
Improvement in HA and IV-C levels were significantly 
greater in the active treatment group compared with that 
in the control group (P<0.05, Table 4). 
Changes in B-mode Ultrasonographic Findings 
After treatment, the inner diameter of the trunk of the 
portal vein and the thickness of the splenic hilum were 
significantly reduced in both groups (P<0.05, Table 5). 
Table 1. Overall response rates, cases (%) 
Group Cases Significant Response Response Failure Overall Response Rate (%) 
Control 75 29 34 12 84 
Active treatment 75 22 37 16 78.67 
Table 2. Changes in liver function ( xfs) U/L
Control  Active treatment  Group Cases 
Before treatment After treatment Before treatment After treatment 
ALT(U/L) 75 156.34±46.78 43.28±12.46ˆ 143.45±31.83 47.62±22.37ˆ
AST(U/L) 75 86.48±31.47 38.65±16.61ˆ 78.52±21.38 43.26±11.85ˆ
GGT(U/L) 75 82.16±28.73 49.23±18.65ˆ 85.43±17.43 37.34±6.23ˆˆ
Notes:*indicates P<0.05 compared with pretreatment values; **indicates P<0.01 compared with the control group.  
Table 3. Changes in HBV-DNA ( xfs) copies
Group Cases Before treatment After treatment 
Control 75 19.24±4.38 10.45±3.38ˆ
Active treatment 75 18.35±3.43 12.67±2.43ˆ
Notes:* indicates P<0.01 compared with pretreatment values. 
Table 4. Changes in liver fibrosis markers ( xfs) 
Active treatment  Control group Group Cases 
Before treatment After treatment Before treatment After treatment 
HA (ng/mL) 75 145.23±32.56 113.43±14.28ˆ¨ 152.64±23.41 117.45±13.78ˆ
IV-C (ug/mL) 75 123.65±32.18 87.47±14.12ˆ¨ 118.43±23.45 98.21±18.45ˆ
PC-III (ug/mL) 75 155.24±27.45 135.27±23.64ˆ 147.24±24.28 128.78±22.52 
LN (ng/mL) 75 108.61±19.76 112.45±17.64 111.42±16.28 108.21±15.42 
Notes: *indicates P<0.01 compared with pretreatment values; ¨indicates P<0.05 compared with the control group. 
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Table 5. Changes in B-mode ultrasonographic findings (cm) 
Control  Active Treatment Group Cases
Before treatment After treatment Before treatment After treatment 
Inner diameter of the portal vein trunk 75 1.43±0.56 1.15±0.31ˆ 1.38±0.38 1.07±0.27ˆ
Thickness of the splenic hilum  75 5.08±0.56 3.21±0.75ˆ 4.84±0.46 3.53±0.21ˆ
Notes: *indicates P<0.05 compared with pretreatment values. 
Changes in Quality of Life Scores 
After treatment with the Ganning formula or oral 
entecavir, the scores of each domain and the total score 
were significantly increased (P<0.05), especially the 
scores of the physiological and psychological domains 
(P<0.01). Patients treated with the Ganning formula had 
significantly greater improvements in the physiological 
score and the total score compared with those in controls 
(P<0.01, Table 6). 
Changes in Psychological and Social Functioning  
Before treatment, most of the patients in both groups had 
varying degrees of psychological disorders and social 
disability. Treatment with the Ganning formula or 
entecavir was associated with significant improvements 
in psychological and social functioning (P<0.01). The 
improvements achieved by the Ganning formula were 
significantly greater compared with those with oral 
entecavir (P<0.05, Table 7).
Table 6. Changes in quality of life scores ( xfs) 
Group Cases Time Physiological 
Domain 
Psychological 
Domain 
Social Domain Environmental 
Domain 
Total Score
Before treatment 13.34±2.36 13.82±2.49 14.53±2.20 12.98±2.06 58.35±10.35Active 
Treatment 
75 
After treatment  18.75±2.32¨Ÿ    19.37±2.51¨Ÿ  16.13±2.19ˆ  13.78±2.35ˆ 75.39±9.82ˆ
Before treatment 13.51±2.43 12.97±2.78 14.62±2.15 13.14±2.33 56.36±11.42Control 75 
After treatment 17.02±1.97¨ 17.24±2.15¨ 15.19±2.32ˆ 14.06±2.26ˆ 68.71±10.17
Notes: *indicates P<0.05, ¨indicates P<0.01 compared with pretreatment values; Ʒindicates P<0.01 compared with the control group. 
Table 7. Changes in psychological and social functioning 
SAS SDS SDSS Group Time 
Normal Mild Moderate Severe Normal Mild Moderate Severe Disabled Nondisabled
Before 
treatment 
2 32 35 6 3 31 33 8 69 6 Active 
Treatment 
(Cases=75) After 
treatment 
18¨ 33¨ 23¨ 1¨ 20¨ 32¨ 20¨ 3¨ 31¨ 44¨
Before 
treatment 
2 29 38 6 2 30 34 9 67 8 Control 
(Cases=75) 
After 
treatment 
10ˆ 34ˆ 28ˆ 3ˆ 13ˆ 33ˆ 25ˆ 4ˆ 46ˆ 29ˆ
Notes: *indicates P<0.01 compared with pretreatment values; ¨indicates P<0.05 compared with the control group. 
Safety and Adverse Effects 
During treatment, none of the patients receiving the 
active treatment had adverse events except for one 
patient who had mild upper abdominal discomfort, which 
resolved after temporary discontinuation of treatment. 
Regular laboratory tests (including hematology, 
urinalysis, a fecal test, renal function [BUN, Cr] and 
electrocardiograms) revealed no abnormal changes in 
any patients in either group. 
DISCUSSION 
Hepatic fibrosis, characterized by deposition of the 
extracellular matrix and histological remodeling, is 
caused by activation of hepatic stellate cells (HSC) and 
metabolism imbalance (generation > degradation) of the 
extracellular matrix including collagens due to chronic 
stimulation of the liver by various damaging factors such 
as hepatitis virus infection, use of alcohol, drugs and 
toxic substances, schistosomiasis, metabolism and 
genetics, cholestasis, and autoimmune liver diseases.13,14
The incidence of hepatitis B is high in China and hepatic 
fibrogenesis is mainly attributable to HBV infection.3,15
In a prospective study, the annual incidence of 
progression from chronic hepatitis B to cirrhosis was 
estimated to be 2.1%;16 in another study, 23% of the 
patients progressed from HBeAg-negative chronic 
hepatitis B to cirrhosis during a mean follow-up of 9 
years (1–18.4).17 Therefore, inhibition of liver fibrosis is 
critical for the management of chronic liver disease. 
Early and effective inhibition of liver fibrosis is 
important for delaying and preventing the progression of 
liver disease. 
Although antiviral agents have a positive role in the 
treatment of liver fibrosis, progression to cirrhosis or 
even hepatocellular carcinoma may still be observed in 
some patients who do not respond well to antiviral 
therapy. With their multi-linked, multi-level, and 
multi-target pharmacological effects, Chinese herbal 
preparations have been shown to be uniquely 
advantageous in the management of liver fibrosis and 
have generated growing interest in the medical 
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community. The anti-fibrotic effects of Chinese herbal 
preparations appear to be associated with their inhibitory 
activity against viruses, inflammation, necrosis and lipid 
peroxidation, resulting in preservation of hepatocytes, 
alleviated symptoms, better liver function, improved 
liver microcirculation, reduced hepatic sinusoidal 
capillarization, less HSC activation, increased 
degradation of extracellular matrix components (EMC), 
and reduced EMC deposition. The Ganning formula is an 
empirical therapy used by practitioners of traditional 
Chinese medicine, Zhuang medicine and/or Yao 
medicine for the treatment of chronic liver diseases in 
Guangxi, China. Our previous studies in cirrhotic rats 
and patients18,19 showed that the Ganning formula was 
associated with reduced malondialdehyde and ALT, 
increased glutathione and superoxide dismutase levels, 
enhanced protection against oxidant injury, increased 
portal venous flow and splenic venous flow, and 
decreased portal hypertension. We have received a patent 
for the invention of the Ganning preparation (Patent No. 
ZL200710051908.5). In the present study, the overall 
response rate in the active treatment group was not 
significantly different from that in the control group 
(78.67% vs. 84%), suggesting that the Ganning 
preparation is as effective as the antiviral agent entecavir 
alone for the treatment of liver fibrosis. 
Current treatment of liver fibrosis focuses mainly on 
eliminating possible causes such as reducing 
inflammation or inhibiting the host immune response, 
inhibiting activation and proliferation of HSC, increasing 
ECM degradation, and promoting hepatocyte 
regeneration. Elimination of causative factors or 
management of primary diseases remains to be the most 
basic and effective measure in the prevention of 
occurrence and development of liver fibrosis. Entecavir 
is an agent with confirmed efficacy for clinical treatment 
of HBV infection. This agent works by reducing HBV 
replication in liver cells through inhibition of HBV-DNA 
polymerase. It is associated with several advantages such 
as a late onset and a low incidence of drug-resistance 
mutation, and good tolerability in long-term use.20-22 The 
present study used entecavir as a comparator and found 
that the Ganning formula significantly decreased viral 
load to a similar extent as entecavir (both P<0.01), 
suggesting a favorable anti-HBV effect of the Ganning 
formula. Active treatment with the Ganning formula was 
associated with significant decreases in the levels of liver 
fibrosis markers (HA, IV-C and PC-III) and liver 
function parameters (ALT, AST and GGT) (P<0.01), and 
the inner diameter of the trunk of the portal vein and the 
thickness of the splenic hilum (P<0.05). This indicates 
that the Ganning formula appears to inhibit fibrogenesis 
by reducing HBV replication in liver cells, alleviating 
inflammation in and around the portal area, and 
decreasing proliferation and deposition of EMC through 
inhibition of HBV-DNA polymerase. Our results of 
virology, biochemistry and imaging of the liver 
confirmed an anti-fibrotic effect of the Ganning formula. 
Among various serum fibrosis markers, HA has been 
found to be the most sensitive and specific marker and 
therefore plays an important role in monitoring the 
progression of fibrosis and evaluating treatment 
outcomes.23 IV-C is highly sensitive and specific for the 
diagnosis of liver fibrosis and IV-C combined with HA is 
more specific than either alone.24,25 In addition, IV-C and 
HA have a good correlation with the stage and grade of 
liver fibrosis.26-27 In this study, serum fibrosis markers 
including LN, HA, IV-C and PC-III were used for 
assessing treatment outcomes. The results of this study 
showed that the Ganning formula was associated with 
significant improvements in HA, IV-C and PC-III and 
that these improvements in HA and IV-C were 
significantly greater with the Ganning formula than with 
the comparator entecavir (P<0.05). This suggests that 
this Chinese herbal compound has the potential to delay 
and prevent liver fibrosis and is more effective in 
improving fibrosis markers such as HA and IV-C 
compared with the antiviral agent entecavir alone. 
A new medical mode has been proposed to be expanded 
to include not only physiological and pathological 
parameters for assessing health status, disease activity 
and outcomes, but also psychological and social 
functioning parameters for evaluating quality of life.28-32
Researchers are increasingly aware of the fact that 
patients with chronic liver disease are more likely to 
have a poor quality of life and that most of these patients 
suffer from a poor psychological state and social 
disability.29-32 In this study, we incorporated assessment 
of quality of life and psychological and social 
functioning as part of the overall evaluation of the 
efficacy of the Ganning formula. We found that patients 
achieved a significant improvement in quality of life and 
psychological and social functioning after receiving the 
Ganning formula, and that improvement observed in 
patients treated with the Ganning formula was 
significantly better than that in patients taking oral 
entecavir (P<0.01 or P<0.05), indicating an overall 
advantage of the Ganning formula in improving quality 
of life, psychological state and social functioning. This 
advantage may be associated with the multi-linked, 
multi-level, and multi-target pharmacological effects of 
this Chinese herbal combination therapy. 
During treatment in this study, patients receiving the 
active treatment showed no abnormal changes in safety 
parameters and experienced no significant adverse 
effects, suggesting that the Ganning formula is a safe 
option for the treatment of liver fibrosis in patients with 
chronic hepatitis B. 
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